Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Eplontersen · 3 trials · 3 indications
To evaluate the effect of eplontersen compared to placebo on serum transthyretin (TTR) concentration up to 24 weeks
Change from baseline in Cardiopulmonary exercise test peak VO2 at week 52
To characterize the pharmacokinetic (PK) profiles of eplontersen following subcutaneous administration of a single 45 mg dose in healthy Chinese participants
To characterize the pharmacokinetic (PK) profiles of eplontersen following subcutaneous administration of a single 45 mg dose in healthy Chinese participants
To characterize the pharmacokinetic (PK) profiles of eplontersen following subcutaneous administration of a single 45 mg dose in healthy Chinese participants
To characterize the pharmacokinetic (PK) profiles of eplontersen following subcutaneous administration of a single 45 mg dose in healthy Chinese participants
To characterize the pharmacokinetic (PK) profiles of eplontersen following subcutaneous administration of a single 45 mg dose in healthy Chinese participants
| Arm | Type | Description |
|---|---|---|
| Eplontersen | EXPERIMENTAL | Eplontersen by subcutaneous injection once every 4 weeks |
| placebo | PLACEBO_COMPARATOR | Eplontersen-matching placebo by subcutaneous injection once every 4 weeks |
| Eplontersen and ALXN2220 | EXPERIMENTAL | Subcutaneous eplontersen and intravenous ALXN2220 every 4 weeks |
| Eplontersen and placebo | PLACEBO_COMPARATOR | Subcutaneous eplontersen and intravenous placebo every 4 weeks |
| Name | Type | Description |
|---|---|---|
| Eplontersen | DRUG | Eplontersen by subcutaneous injection |
| Placebo | DRUG | Eplontersen-matching placebo by subcutaneous injection |
| ALXN2220 | BIOLOGICAL | ALXN2220 delivered intravenously, once every 4 weeks |
| Eplontersen Solution for Injection | DRUG | an autoinjector with 0.8 mL deliverable volume (at 56 mg/mL concentration) will be provided, total dose is 45 mg. |
Inclusion Criteria: 1. Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements. 2. 20 to 90 years of age (inclusive). 3. Females: must be non-pregnant and non-lactating and either: 1. surgically s...
Eplontersen is an investigational drug being developed for transthyretin amyloid cardiomyopathy (ATTR-CM) and transthyretin-mediated amyloidosis. It is currently in Phase 3 clinical development for these cardiovascular conditions.
Eplontersen is an antisense oligonucleotide (ASO) that targets transthyretin. It is designed to reduce the production of transthyretin protein, which is involved in the development of transthyretin amyloid cardiomyopathy and transthyretin-mediated amyloidosis.
Eplontersen is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN.
Eplontersen is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing to evaluate its safety and efficacy in patients with transthyretin amyloid cardiomyopathy.
Eplontersen is being studied in several clinical trials, including NCT06194825, a Phase 3 study in Chinese subjects with transthyretin amyloid cardiomyopathy; NCT06527755, a Phase 1 study in healthy Chinese volunteers; and NCT07608354, a Phase 2 study evaluating its use with ALXN2220 in adults with ATTR-CM.
No, Eplontersen is not the same as ALXN2220. They are being studied together in a Phase 2 clinical trial to evaluate the efficacy and safety of concomitant use of Eplontersen and ALXN2220 compared with Eplontersen and placebo in adults with ATTR-CM.